Stock Analysis
- Poland
- /
- Medical Equipment
- /
- WSE:MRC
Mercator Medical Full Year 2023 Earnings: zł2.38 loss per share (vs zł19.41 loss in FY 2022)
Mercator Medical (WSE:MRC) Full Year 2023 Results
Key Financial Results
- Revenue: zł514.7m (down 5.2% from FY 2022).
- Net loss: zł19.7m (loss narrowed by 90% from FY 2022).
- zł2.38 loss per share (improved from zł19.41 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Mercator Medical's share price is broadly unchanged from a week ago.
Risk Analysis
You still need to take note of risks, for example - Mercator Medical has 2 warning signs we think you should be aware of.
Valuation is complex, but we're helping make it simple.
Find out whether Mercator Medical is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About WSE:MRC
Mercator Medical
Manufactures and distributes disposable medical gloves, dressings, and non-woven fabric products in Poland, the Czech Republic, Ukraine, France, Hungary, Italy, Romania, Germany, rest of Europe, and Thailand.
Adequate balance sheet and slightly overvalued.